Candesartan Cilexetil

For the treatment of Hypertension, the typical starting dose of Candesartan Cilexetil is 16 mg once daily. Depending on the patient's blood pressure response, the dose may be titrated upward to a maximum of 32 mg daily, administered in one or two divided doses. Most of the antihypertensive effect is observed within 2 weeks, with the full effect occurring within 4 to 6 weeks of consistent therapy. For patients who are volume-depleted (e.g., those on high-dose diuretics), a lower starting dose of 4 mg to 8 mg may be considered to prevent excessive hypotension.

In the management of Heart Failure, the recommended starting dose is 4 mg once daily. Healthcare providers typically aim to double the dose at intervals of approximately 2 weeks, as tolerated by the patient, reaching a target maintenance dose of 32 mg once daily. Clinical trials, such as the CHARM program, have demonstrated that these higher target doses provide the greatest benefit in reducing cardiovascular death and hospitalizations.

Candesartan Cilexetil is approved for the treatment of hypertension in children aged 1 to <17 years. The dosage is based on body weight:

• Children < 6 years: The starting dose is 0.2 mg/kg per day, with a range of 0.05 to 0.4 mg/kg per day.
• Children ≥ 6 years (< 50 kg): The starting dose is 4 mg to 8 mg daily, titrated up to 16 mg if necessary.
• Children ≥ 6 years (≥ 50 kg): The starting dose is 8 mg to 16 mg daily, titrated up to 32 mg if necessary.

Note: Candesartan Cilexetil is not recommended for use in infants younger than 1 year of age due to the risk of abnormal kidney development.

Renal Impairment

For patients with mild renal impairment, no initial dosage adjustment is usually necessary. However, in patients with moderate to severe renal impairment or those on dialysis, a lower starting dose (e.g., 8 mg for hypertension) and careful monitoring of serum potassium and creatinine levels are required. The drug is not significantly removed by hemodialysis.

Hepatic Impairment

In patients with mild hepatic impairment, dosage adjustments are generally not required. For those with moderate hepatic impairment, a lower starting dose (e.g., 8 mg) should be considered. There is limited clinical data regarding the use of Candesartan Cilexetil in patients with severe hepatic impairment, and it should be used with extreme caution in this population.

Elderly Patients

No initial dosage adjustment is typically required for elderly patients (over 65 years), although healthcare providers should be mindful that this population may be more sensitive to the blood pressure-lowering effects and may have underlying renal insufficiency.

Candesartan Cilexetil should be taken exactly as prescribed by your healthcare provider. It is usually taken once daily at the same time each day to maintain consistent blood levels. The tablets can be taken with or without food. If you have difficulty swallowing tablets, discuss alternative options with your pharmacist. Do not crush or split the tablets unless specifically instructed to do so by your doctor, as this may affect the drug's release profile. Store the medication at room temperature, away from moisture and direct heat.

If you miss a dose of Candesartan Cilexetil, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at once to make up for a missed one, as this increases the risk of side effects like severe dizziness or fainting.

Signs of an overdose of Candesartan Cilexetil primarily relate to excessive blood pressure reduction (hypotension) and may include severe dizziness, a rapid or slow heartbeat (tachycardia or bradycardia), and fainting. If an overdose is suspected, seek emergency medical attention immediately. Treatment is generally supportive, involving fluid replacement to restore blood pressure and monitoring of vital signs.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop taking this medication without medical guidance, as sudden discontinuation can lead to a rapid increase in blood pressure.

In clinical trials for hypertension, Candesartan Cilexetil was generally well-tolerated, with side effects being similar to those seen with a placebo. However, some patients may experience:

• Dizziness or Lightheadedness: This is most common when first starting the medication or after a dose increase. It occurs as the body adjusts to lower blood pressure.
• Back Pain: Some patients report mild to moderate musculoskeletal discomfort.
• Upper Respiratory Tract Infection: Symptoms such as a stuffy nose, sore throat, or cough may occur, though these are often not directly caused by the drug itself but were noted in clinical cohorts.

These effects may occur in a subset of patients and should be monitored:

• Fatigue and Asthenia: A general feeling of tiredness or lack of energy.
• Hyperkalemia: Elevated levels of potassium in the blood. This is more common in patients with heart failure or underlying kidney disease. Symptoms may include muscle weakness or an irregular heartbeat.
• Hypotension: Symptomatic low blood pressure, particularly in patients who are dehydrated or taking other diuretics.
• Headache: Persistent but usually mild head pain.

Rare but documented side effects include:

• Renal Function Impairment: In susceptible individuals (e.g., those with renal artery stenosis), the drug may cause a rise in blood urea nitrogen (BUN) and serum creatinine.
• Hyponatremia: Low sodium levels in the blood, which can cause confusion or seizures if severe.
• Hematologic Changes: Rare cases of agranulocytosis (low white blood cell count) or leukopenia have been reported.

> Warning: Stop taking Candesartan Cilexetil and call your doctor immediately if you experience any of the following serious symptoms:

• Angioedema: Swelling of the face, lips, tongue, or throat, which can cause difficulty breathing or swallowing. This is a medical emergency.
• Signs of Kidney Failure: A significant decrease in urine output, swelling in the feet or ankles, or shortness of breath.
• Severe Hyperkalemia: Chest pain, palpitations, or profound muscle weakness.
• Liver Problems: Yellowing of the skin or eyes (jaundice), dark urine, or severe abdominal pain.
• Severe Allergic Reaction: Hives, skin rash, or blistering and peeling skin (Stevens-Johnson Syndrome).

Prolonged use of Candesartan Cilexetil is generally considered safe and effective for managing chronic conditions. The primary long-term concern is the potential for gradual changes in kidney function, especially in patients with pre-existing renal disease or those taking other medications that affect the kidneys (like NSAIDs). Periodic blood tests to monitor creatinine and potassium levels are standard practice for long-term therapy. Some studies have investigated the drug's effect on glucose metabolism, generally finding it to be metabolic-neutral or even slightly beneficial compared to older antihypertensives like beta-blockers.

Candesartan Cilexetil carries a Boxed Warning regarding Fetal Toxicity. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios (low amniotic fluid) can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, Candesartan Cilexetil should be discontinued as soon as possible.

Report any unusual symptoms or persistent side effects to your healthcare provider to ensure your treatment remains safe and effective.

Candesartan Cilexetil is a powerful cardiovascular medication that requires careful medical supervision. Patients must be aware that while the drug is effective at lowering blood pressure, it does not "cure" hypertension; rather, it manages it. It is vital to continue taking the medication even if you feel well, as high blood pressure often has no outward symptoms. Patients should also be cautioned about the risk of "first-dose hypotension," where the blood pressure drops significantly after the very first dose, especially if they are also taking high-dose diuretics or are dehydrated.

Fetal Toxicity: Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, Candesartan Cilexetil should be discontinued as soon as possible. Exposure to ARBs during the second and third trimesters is associated with serious fetal injuries, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. If a patient becomes pregnant while on this medication, they must contact their healthcare provider immediately to transition to a safer antihypertensive alternative.

• Anaphylaxis and Angioedema: There is a risk of severe allergic reactions. Patients with a history of angioedema (swelling of the deep layers of the skin) with other medications, particularly ACE inhibitors, should use Candesartan Cilexetil with caution, although the risk is lower than with ACE inhibitors.
• Renal Function Impairment: As a consequence of inhibiting the RAAS, changes in renal function may be anticipated in susceptible individuals. In patients whose renal function may depend on the activity of the RAAS (e.g., patients with severe congestive heart failure), treatment with ARBs has been associated with oliguria and/or progressive azotemia. Patients with bilateral renal artery stenosis are at particularly high risk for acute renal failure.
• Hyperkalemia: Candesartan can cause an increase in serum potassium. This risk is heightened in patients with renal impairment, diabetes mellitus, or those using potassium-sparing diuretics or potassium supplements. Regular monitoring of electrolytes is essential.
• Hypotension in Volume-Depleted Patients: In patients with an activated renin-angiotensin system, such as those receiving high doses of diuretics, symptomatic hypotension may occur. These conditions should be corrected prior to administration of Candesartan Cilexetil.

Healthcare providers will typically require the following monitoring parameters:

• Blood Pressure: Regular checks to ensure the medication is achieving the target pressure.
• Renal Function Tests: Serum creatinine and BUN levels should be checked periodically, especially in the first few weeks of therapy and after dose adjustments.
• Serum Potassium: Electrolyte panels are necessary to screen for hyperkalemia.
• Pediatric Monitoring: In children, blood pressure and renal function require close monitoring due to the developing nature of their physiological systems.

Candesartan Cilexetil may cause dizziness or fatigue, particularly at the start of treatment or when the dose is increased. Patients should observe how they react to the medication before driving, operating heavy machinery, or performing other tasks that require alertness.

Alcohol can enhance the blood pressure-lowering effect of Candesartan Cilexetil, which may lead to increased dizziness, lightheadedness, or fainting. It is generally advised to limit alcohol consumption while taking this medication.

Do not stop taking Candesartan Cilexetil abruptly. While it does not typically cause a "rebound" effect like some beta-blockers, your blood pressure will likely rise quickly once the medication is stopped, increasing your risk of cardiovascular events. If discontinuation is necessary, your doctor will provide a plan to transition to another therapy.

> Important: Discuss all your medical conditions, including any history of liver or kidney disease, with your healthcare provider before starting Candesartan Cilexetil.

• Aliskiren: The use of Candesartan Cilexetil in combination with aliskiren (a direct renin inhibitor) is strictly contraindicated in patients with diabetes mellitus. This combination significantly increases the risk of renal impairment, hyperkalemia, and hypotension. In patients with moderate to severe renal impairment (GFR < 60 mL/min), this combination should also generally be avoided.
• Dual RAAS Blockade: Combining Candesartan Cilexetil with an ACE inhibitor (like lisinopril) or another ARB is generally not recommended. While it was previously explored for heart failure, clinical data suggests that dual blockade increases the risk of adverse events (renal failure, hyperkalemia) without providing significant additional benefit for most patients.

• Lithium: ARBs, including candesartan, can reduce the renal excretion of lithium, leading to increased serum lithium levels and lithium toxicity. If this combination is necessary, lithium levels must be monitored frequently, and the patient should be watched for signs of toxicity (tremors, confusion, nausea).
• Potassium-Sparing Diuretics: Drugs such as spironolactone, triamterene, or amiloride can lead to additive effects on serum potassium. Concurrent use requires very close monitoring of potassium levels to prevent life-threatening hyperkalemia.
• Potassium Supplements: Over-the-counter potassium supplements or salt substitutes containing potassium should be avoided unless specifically directed by a physician.

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Medications like ibuprofen, naproxen, and selective COX-2 inhibitors (e.g., celecoxib) can interfere with the antihypertensive effect of Candesartan Cilexetil. Furthermore, in patients who are elderly, volume-depleted, or have compromised renal function, the co-administration of an ARB and an NSAID may result in further deterioration of renal function, including possible acute renal failure.
• Other Antihypertensives: While often used together intentionally, combining candesartan with other blood pressure medications (beta-blockers, calcium channel blockers) increases the risk of hypotension. Dosage adjustments may be required.

Candesartan Cilexetil does not have significant interactions with most foods. Unlike some other cardiovascular drugs, it does not interact with grapefruit juice. However, patients should be cautious with Salt Substitutes. Many salt substitutes contain potassium chloride instead of sodium chloride; using these while on an ARB can lead to dangerously high potassium levels.

• St. John's Wort: While not a direct metabolic interaction, some herbal supplements that affect blood pressure should be used with caution.
• Natural Licorice: Can cause sodium retention and potassium loss, potentially counteracting the effects of the medication.
• Hawthorn: May have mild antihypertensive properties and could theoretically increase the effect of candesartan.

Candesartan Cilexetil does not typically interfere with common laboratory tests, although it will obviously affect results for serum creatinine, BUN, and potassium. In rare cases, it may cause slight decreases in hemoglobin and hematocrit, but these are rarely clinically significant.

For each major interaction, the management strategy usually involves more frequent monitoring of clinical parameters (blood pressure, kidney function, electrolytes) or adjusting the dosage of one or both medications.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those purchased over-the-counter.

Candesartan Cilexetil must NEVER be used in the following circumstances:

• Pregnancy: Due to the proven risk of fetal toxicity and death, this medication is absolutely contraindicated in the second and third trimesters of pregnancy. It should be avoided in the first trimester as well.
• Known Hypersensitivity: Patients who have had a previous severe allergic reaction (anaphylaxis, angioedema) to candesartan or any component of the tablet formulation must not take this drug.
• Concomitant Aliskiren in Diabetes: As noted in the interactions section, the use of candesartan with aliskiren in patients with diabetes is contraindicated due to the high risk of severe adverse outcomes.

These conditions require a careful risk-benefit analysis by a healthcare provider:

• Severe Renal Impairment: While not an absolute contraindication, patients with a GFR < 30 mL/min require very low starting doses and intensive monitoring.
• Bilateral Renal Artery Stenosis: In these patients, the drug can cause a rapid decline in kidney function because the kidneys rely on angiotensin II-mediated vasoconstriction of the efferent arteriole to maintain filtration pressure.
• Aortic or Mitral Valve Stenosis: Patients with significant valvular obstruction may be at risk for decreased coronary perfusion if their blood pressure is lowered too aggressively.
• Hyperkalemia: If a patient already has high potassium levels, starting an ARB may exacerbate the condition to dangerous levels.

Patients who have experienced angioedema while taking an ACE inhibitor (e.g., lisinopril, enalapril) may be at a slightly increased risk of experiencing angioedema with Candesartan Cilexetil. While the mechanism of angioedema differs between the two classes (ACE inhibitors involve bradykinin, while ARBs do not), clinical caution is advised. Most patients who cannot tolerate ACE inhibitors due to cough can safely take ARBs, but those with a history of airway-threatening angioedema should be evaluated carefully.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of heart, liver, or kidney disease, before prescribing Candesartan Cilexetil.

Candesartan Cilexetil is classified as FDA Pregnancy Category D. This means there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. If a patient is planning to become pregnant, they should discuss alternative blood pressure medications with their doctor before conceiving. If pregnancy is confirmed during therapy, the drug must be stopped immediately.

It is not known whether candesartan is excreted in human breast milk. However, candesartan has been found in the milk of lactating rats. Because of the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. In most cases, alternative antihypertensives with more safety data in breastfeeding (such as methyldopa or certain beta-blockers) are preferred.

Candesartan Cilexetil is indicated for hypertension in children 1 year of age and older. It has not been studied in children younger than 1 year. In neonates and infants, the kidneys are still developing; drugs that act on the RAAS can interfere with this development. Therefore, it is strictly contraindicated in children under 12 months of age. Clinical trials in older children have shown a safety profile similar to that in adults, though weight-based dosing is critical.

Of the total number of subjects in clinical studies of Atacand, approximately 21% were 65 and over, while 3% were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. However, elderly patients are more likely to have decreased renal function and may be taking multiple other medications (polypharmacy), increasing the risk of drug interactions and hypotension-related falls. Healthcare providers should start at the lower end of the dosing range and monitor closely.

In patients with renal impairment, serum concentrations of candesartan are increased. For those with moderate to severe impairment or those on hemodialysis, the recommended starting dose is 8 mg once daily for hypertension. Close monitoring of potassium and creatinine is mandatory. Candesartan is not dialyzable.

Patients with moderate hepatic impairment have been shown to have an increase in the AUC of candesartan by about 145%. A starting dose of 8 mg is recommended for these patients. No specific data is available for severe hepatic impairment, and use in such patients is generally discouraged unless the benefits clearly outweigh the risks.

> Important: Special populations require individualized medical assessment and frequent follow-up to ensure medication safety.

Candesartan Cilexetil is an ester prodrug that is hydrolyzed to candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 receptor antagonist. It binds competitively and with high affinity to the AT1 receptor, which is the receptor responsible for the known physiological effects of angiotensin II, such as vasoconstriction, stimulation of aldosterone synthesis and release, cardiac stimulation, and renal reabsorption of sodium. By blocking these effects, candesartan lowers blood pressure and improves the hemodynamics in heart failure. It does not inhibit ACE (kininase II), and therefore does not interfere with the breakdown of bradykinin, making it much less likely to cause the dry cough associated with ACE inhibitors.

Candesartan inhibits the pressor effects of angiotensin II infusions in a dose-dependent manner. After a single oral dose, the antihypertensive effect usually begins within 2 hours, with peak reduction in blood pressure occurring within 4 to 8 hours. The effect lasts for at least 24 hours. With repeated dosing, the maximum reduction in blood pressure is generally attained within 4 to 6 weeks. There is no evidence of a rebound effect after sudden cessation of the drug. In heart failure patients, candesartan reduces systemic vascular resistance and pulmonary capillary wedge pressure.

| Parameter | Value |

|---|---|

| Bioavailability | ~15% (as active candesartan) |

| Protein Binding | >99% (primarily albumin) |

| Half-life | ~9 hours |

| Tmax | 3 to 4 hours |

| Metabolism | Minimal (minor CYP2C9 activity) |

| Excretion | Renal 33%, Fecal 67% |

• Molecular Formula: C33H34N6O6
• Molecular Weight: 610.66 g/mol
• Solubility: Practically insoluble in water; sparingly soluble in methanol.
• Structure: It is a tetrazole derivative containing a benzimidazole group and a cilexetil ester moiety that facilitates oral absorption.

Candesartan Cilexetil is classified as an Angiotensin II Receptor Blocker (ARB). Other drugs in this class include losartan, valsartan, and irbesartan. Within the broader therapeutic area of antihypertensives, ARBs are considered a primary choice for patients with diabetes, chronic kidney disease, or heart failure due to their organ-protective properties.